Moolec Science (MLECW) Non-Current Debt (2023 - 2025)
Moolec Science (MLECW) posted Non-Current Debt of $1.3 million for Q2 2025, down 93.04% sequentially from $19.4 million in Q4 2024, and down 98.94% YoY from $127.2 million in Q2 2024.
Moolec Science (MLECW) Non-Current Debt (2023 - 2025) Analysis & Trends
Moolec Science has reported Non-Current Debt for 3 years, with the latest figure at $1.3 million in Q2 2025.
- Quarterly Non-Current Debt fell 98.94% year-over-year to $1.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.3 million (down 98.94% YoY) and the FY2025 annual result came in at $1.3 million, down 98.94% from the prior year.
- Non-Current Debt declined to $1.3 million in Q2 2025 per MLECW's latest filing, from $19.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $127.2 million in Q2 2024 and troughed at $1.2 million in Q1 2023.
- A 3-year average of $26.6 million and a median of $5.2 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt soared 4897.49% in 2024, then tumbled 98.94% in 2025.
- Over 3 years, Non-Current Debt stood at $7.8 million in 2023, then jumped by 146.91% to $19.4 million in 2024, then slumped by 93.04% to $1.3 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.3 million, $19.4 million, and $127.2 million for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.35 Mn |
| Dec 31, 2024 | 19.37 Mn |
| Jun 30, 2024 | 127.25 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | 1.18 Mn |